Fennec Reports Positive Phase 3 Data
Insights - Fennec (FENC) presented the full data from SIOPEL 6, a Phase 3 study in cisplatin induced hearing loss in children with Standard Risk Hepatoblastoma (SR-HB). The study … Continue Reading
Read NowInsights
Short Tyme Technologies As Dilution is Imminent
Insights - Short-sell Tyme Technologies (NASDAQ: TYME) at ~$6 a share Cover (buy-back) this short at <$3 a share by year-end We are short Tyme Technologies (“Tyme”), a $500m+ … Continue Reading
Read Now
How To Profit From Zogenix’s Upcoming Data
Insights - Zogenix (ZGNX) will be releasing data from its pivotal Phase 3 program of ‘ZX008’ intended for the treatment of Dravet Syndrome (DS), a form of … Continue Reading
Read Now
Update on Open Ideas – Bluebird Bio, Revance, Sage and More
Insights - We have outlined our reasoning behind certain position changes in our open/closed positions, which can be found on PropThink’s Recent Research page. Bluebird Fairly Valued … Continue Reading
Premium: Read Now
Shares of This Orphan Drug Company Deeply Undervalued Even After Data Readout
Insights - Fennec Pharmaceuticals (FENC:NASDAQ) (FRX.TO:TSX) released the results of its long anticipated Phase 3 study. Interim data showed Fennec’s drug, sodium thiosulfate (“STS”) significantly reduces chemotherapy … Continue Reading
Read Now
Some Reprieve for Biopharma (!)
Insights - After a much-needed meeting between pharmaceutical representatives and Donald Trump this morning, biopharma stocks are rallying. To summarize, Trump’s comments after the meeting (a 10-minute … Continue Reading
Read Now
Trump Takes Aim At Drug Companies, Again
Insights - In case you haven’t already seen the quotes, Donald Trump took aim at the pharmaceutical industry in a press conference this afternoon, sending bio/pharma stocks … Continue Reading
Read Now